13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001306923
Total reported value
$723.7M
$723.7M
44 檔
39.0%
As reported in its official Q1 2025 Form 13F filing, Palo Alto Investors LP's tracked investment portfolio stood at $723.7M with 44 total positions.
Palo Alto Investors LP executed strategic sector rebalancing during Q1 2025, establishing 26 new positions while fully exiting 24 holdings and trimming 11 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 14.34% | -4.29% | -38.44% | |
| 2 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 13.34% | -0.52% | -7.13% | |
| 3 | AM6 | Amicus Therapeutics Inc | Stock-Other | 11.41% | -2.46% | EXIT | |
| 4 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 8.43% | +0.23% | -3.08% | |
| 5 | UTHR | United Therapeutics CORP | Stock-Healthcare | 6.18% | -1.01% | -32.42% | |
| 6 | BIIB | Biogen Inc | Stock-Healthcare | 5.34% | +0.24% | +7.77% | |
| 7 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 4.29% | — | -40.65% | |
| 8 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 3.92% | +0.76% | +4.60% | |
| 9 | PRTA | Prothena Corporation plc | Stock-Other | 3.91% | -0.25% | -4.50% | |
| 10 | ANAB | Anaptysbio Inc | Stock-Other | 3.61% | +0.22% | +20.94% | |
| 11 | NVCR | NovoCure Limited | Stock-Healthcare | 3.40% | +0.55% | +23.07% | |
| 12 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.56% | — | — | |
| 13 | EHTH | Ehealth Inc | Stock-Other | 2.14% | +0.02% | -10.32% | |
| 14 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 2.04% | -0.37% | +5.58% | |
| 15 | STAA | Staar Surgical Co | Stock-Other | 1.76% | — | +4.84% | |
| 16 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.54% | -0.01% | — | |
| 17 | ALKS | Alkermes plc | Stock-Healthcare | 1.39% | +0.45% | -23.43% | |
| 18 | GOSS | Gossamer Bio Inc | Stock-Other | 1.31% | — | -0.00% | |
| 19 | ALGN | Align Technology Inc | Stock-Healthcare | 1.14% | -0.36% | — | |
| 20 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.04% | -0.48% | +9.67% | |
| 21 | ✓ | Acelyrin Inc | Stock-Other | 0.84% | — | — | |
| 22 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.66% | +0.48% | — | |
| 23 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.56% | +1.05% | — | |
| 24 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 0.54% | +0.01% | — | |
| 25 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.50% | — | — | |
| 26 | BNTX | Biontech Se-adr | Stock-Other | 0.44% | -0.02% | — | |
| 27 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.40% | -0.02% | — | |
| 28 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.38% | +0.27% | — | |
| 29 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.38% | +0.36% | +74.97% | |
| 30 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.28% | +0.06% | — | |
| 31 | NUVB | Nuvation Bio Inc | Stock-Other | 0.26% | -0.07% | — | |
| 32 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 0.25% | +0.01% | — | |
| 33 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.23% | — | -93.40% | |
| 34 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.23% | +0.25% | +36.19% | |
| 35 | HUM | Humana Inc | Stock-Healthcare | 0.20% | +0.11% | — | |
| 36 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.19% | +0.13% | — | |
| 37 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.16% | -0.04% | — | |
| 38 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.13% | — | — | |
| 39 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.10% | +0.02% | — | |
| 40 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.05% | +0.05% | — | |
| 41 | TIL | Instil Bio Inc | Stock-Other | 0.04% | — | — | |
| 42 | ✓ | Akari Therapeutics PLC | Stock-Other | 0.03% | — | — | |
| 43 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.03% | — | — | |
| 44 | GBIOGBX | Generation Bio Co | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AM6 | Amicus Therapeutics Inc | +6.1% | -4.14% | Trim |
| 2 | ACAD | Acadia Pharmaceuticals Inc | +5.3% | -3.08% | Add |
| 3 | INSM | Insmed Inc | +4.9% | -38.44% | Trim |
| 4 | BMRN | Biomarin Pharmaceutical Inc | +3.2% | -7.13% | Trim |
| 5 | ANAB | Anaptysbio Inc | +3% | +20.94% | Add |
| 6 | ALKS | Alkermes plc | +0.7% | -23.43% | Trim |
| 7 | SNDX | Syndax Pharmaceuticals Inc | +0.7% | +9.67% | Add |
| 8 | GOSS | Gossamer Bio Inc | +0.5% | -0.00% | Add |
| 9 | TVTX | Travere Therapeutics Inc | +0.3% | — | Trim |
| 10 | ALDX | Aldeyra Therapeutics Inc | +0.2% | — | Add |
| 11 | URGN | UroGen Pharma Ltd. | 0% | — | Unchanged |
| 12 | UTHR | United Therapeutics CORP | -0.6% | -32.42% | Trim |
| 13 | ALGN | Align Technology Inc | -0.7% | — | Trim |
| 14 | PRTA | Prothena Corporation plc | -1% | -4.50% | Trim |
| 15 | EHTH | Ehealth Inc | -1.6% | -10.32% | Add |
| 16 | BIIB | Biogen Inc | -1.6% | +7.77% | Trim |
| 17 | KPTIEUR | Karyopharm Therapeutics Inc | -2.8% | -93.40% | Trim |
| 18 | STAA | Staar Surgical Co | -8.9% | +4.84% | Trim |
| 19 | ABMDEUR | Abiomed Inc | — | EXIT | Sold out |
| 20 | RVNCEUR | Revance Therapeutics Inc | — | EXIT | Sold out |
| 21 | VNDA | Vanda Pharmaceuticals Inc | — | EXIT | Sold out |
| 22 | EPZMEUR | Epizyme Inc | — | EXIT | Sold out |
| 23 | SG7 | Sage Therapeutics Inc | — | EXIT | Sold out |
| 24 | CLVSEUR | Clovis Oncology Inc | — | EXIT | Sold out |
| 25 | ALNY | Alnylam Pharmaceuticals Inc | — | NEW | New buy |
| 26 | 2JQ | Gritstone Bio Inc | — | EXIT | Sold out |
| 27 | PTCT | Ptc Therapeutics Inc | — | NEW | New buy |
| 28 | NVCR | NovoCure Limited | — | NEW | New buy |
| 29 | ALXN | Alexion Pharmaceuticals Inc | — | EXIT | Sold out |
| 30 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 31 | PBYI | Puma Biotechnology Inc | — | EXIT | Sold out |
| 32 | DRNAUSD | Dicerna Pharmaceuticals Inc | — | EXIT | Sold out |
| 33 | IOVA | Iovance Biotherapeutics Inc | — | NEW | New buy |
| 34 | AGIO | Agios Pharmaceuticals Inc | — | NEW | New buy |
| 35 | KLDO | Kaleido Biosciences Inc | — | EXIT | Sold out |
| 36 | ✓ | Acelyrin Inc | — | NEW | New buy |
| 37 | ✓ | Magenta Therapeutics Inc | — | EXIT | Sold out |
| 38 | ZGNXEUR | Zogenix Inc | — | EXIT | Sold out |
| 39 | ✓ | — | EXIT | Sold out | |
| 40 | DYN | Dyne Therapeutics Inc | — | NEW | New buy |
| 41 | MIRM | Mirum Pharmaceuticals Inc | — | NEW | New buy |
| 42 | EW | Edwards Lifesciences CORP | — | NEW | New buy |
| 43 | RIGLUSD | Rigel Pharmaceuticals Inc | — | EXIT | Sold out |
| 44 | ✓ | Verve Therapeutics Inc | — | NEW | New buy |
| 45 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 46 | BNTX | Biontech Se-adr | — | NEW | New buy |
| 47 | BCYC | Bicycle Therapeutics Plc-adr | — | NEW | New buy |
| 48 | TSHA | Taysha Gene Therapies Inc | — | NEW | New buy |
| 49 | ✓ | Alimera Sciences Inc | — | EXIT | Sold out |
| 50 | NBIX | Neurocrine Biosciences Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Palo Alto Investors LP reported a total U.S. public equity portfolio value of $723.7M across 44 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, BMRN, AM6) accounted for 39.0% of total reported equity market value during Q1 2025.
Top New Position Initiated
ALNY
市值: $22.5M
Top Position Liquidated / Trimmed
ABMDEUR
前期市值: $182.3M
During Q1 2025, Palo Alto Investors LP's top holdings by market value included INSM (14.3%)、BMRN (13.3%)、AM6 (11.4%). The largest single position, INSM, represented 14.3% of total portfolio value.
In Q1 2025, Palo Alto Investors LP made 67 total portfolio adjustments, initiating 26 new buys, adding to 6 positions, trimming 11 holdings, and fully liquidating 24 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.